APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice

Neuroscience Letters

Volumn 560, Issue , 2014, Pages 131-136

  Kunzler, Jacqueline ^a,b   Youmans, Katherine L ^a,c   Yu, Chunjiang ^a   LaDu, Mary Jo ^a   Tai, Leon M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AD transgenic mouse model; Alzheimer's disease; Amyloid ; APOE; Estrogen; Soluble A

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ESTRADIOL;

AMYLOID PLAQUE; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN CORTEX; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; GENETIC RISK; HIPPOCAMPUS; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL;

AD; AD TRANSGENIC MOUSE MODEL; ALZHEIMER'S DISEASE; AMYLOID-Β; APOE; APOLIPOPROTEIN E; AΒ; ESTROGEN; ESTROGEN THERAPY; ET; FAD; FAMILIAL AD; HORMONE REPLACEMENT THERAPY; HRT; OVARIECTOMY; OVARIECTOMY WITH ET; OVARIECTOMY WITHOUT ET; OVX; OVX(ET+); OVX(ET-); SOLUBLE AΒ; THIO-S; THIOFLAVIN S;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; ESTRADIOL; ESTROGENS; MICE, TRANSGENIC; MUTATION; OVARIECTOMY; PLAQUE, AMYLOID;

EID: 84891706013     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.12.032     Document Type: Article

References (24)

1. Andersen K., Launer L.J., Dewey M.E., Letenneur L., Ott A., Copeland J.R., Dartigues J.F., Kragh-Sorensen P., Baldereschi M., Brayne C., Lobo A., Martinez-Lage J.M., Stijnen T., Hofman A. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM incidence research group. Neurology 1999, 53:1992-1997.
2. Bretsky P.M., Buckwalter J.G., Seeman T.E., Miller C.A., Poirier J., Schellenberg G.D., Finch C.E., Henderson V.W. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Disease and Associated Disorders 1999, 13:216-221.
3. Carroll J.C., Rosario E.R., Chang L., Stanczyk F.Z., Oddo S., LaFerla F.M., Pike C.J. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:13357-13365.
4. Corder E.H., Ghebremedhin E., Taylor M.G., Thal D.R., Ohm T.G., Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Annals of the New York Academy of Sciences 2004, 1019:24-28.
5. Espeland M.A., Rapp S.R., Shumaker S.A., Brunner R., Manson J.E., Sherwin B.B., Hsia J., Margolis K.L., Hogan P.E., Wallace R., Dailey M., Freeman R., Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA: The Journal of the American Medical Association 2004, 291:2959-2968.
6. Fleisher A., Grundman M., Jack C.R., Petersen R.C., Taylor C., Kim H.T., Schiller D.H., Bagwell V., Sencakova D., Weiner M.F., DeCarli C., DeKosky S.T., van Dyck C.H., Thal L.J. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Archives of Neurology 2005, 62:953-957.
7. Jacobs E.G., Kroenke C., Lin J., Epel E.S., Kenna H.A., Blackburn E.H., Rasgon N.L. Accelerated cell aging in female APOE-epsilon4 carriers: implications for hormone therapy use. PLoS One 2013, 8:e54713.
8. Kang J.H., Grodstein F. Postmenopausal hormone therapy, timing of initiation APOE and cognitive decline. Neurobiology of Aging 2012, 33:1129-1137.
9. Kang J.H., Weuve J., Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 2004, 63:101-107.
10. Nequin L.G., Alvarez J., Schwartz N.B. Measurement of serum steroid and gonadotropin levels and uterine and ovarian variables throughout 4 day and 5 day estrous cycles in the rat. Biology of Reproduction 1979, 20:659-670.
11. Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Archives of Internal Medicine 1996, 156:2213-2217.
12. Payami H., Zareparsi S., Montee K.R., Sexton G.J., Kaye J.A., Bird T.D., Yu C.E., Wijsman E.M., Heston L.L., Litt M., Schellenberg G.D. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. American Journal of Human Genetics 1996, 58:803-811.
13. Resnick S.M., Coker L.H., Maki P.M., Rapp S.R., Espeland M.A., Shumaker S.A. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clinical Trials 2004, 1:440-450.
14. Ryan J., Carriere I., Scali J., Dartigues J.F., Tzourio C., Poncet M., Ritchie K., Ancelin M.L. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C study. Neurology 2009, 73:1729-1737.
15. Slowinska-Srzednicka J., Zgliczynski S., Jeske W., Stopinska-Gluszak U., Srzednicki M., Brzezinska A., Zgliczynski W., Sadowski Z. Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. Journal of Endocrinological Investigation 1992, 15:533-538.
16. Valen-Sendstad A., Engedal K., Stray-Pedersen B., Group A.S., Strobel C., Barnett L., Meyer N., Nurminemi M. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone,. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry 2010, 18:11-20.
17. Verghese P.B., Castellano J.M., Holtzman D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurology 2011, 10:241-252.
18. Waring S.C., Rocca W.A., Petersen R.C., O'Brien P.C., Tangalos E.G., Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999, 52:965-970.
19. Wharton W., Baker L.D., Gleason C.E., Dowling M., Barnet J.H., Johnson S., Carlsson C., Craft S., Asthana S. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. Journal of Alzheimer's Disease: JAD 2011, 26:495-505.
20. Yaffe K., Haan M., Byers A., Tangen C., Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000, 54:1949-1954.
21. Youmans K.L., Leung S., Zhang J., Maus E., Baysac K., Bu G., Vassar R., Yu C., Ladu M.J. Amyloid-beta42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. Journal of Neuroscience Methods 2011, 196:51-59.
22. Youmans K.L., Tai L.M., Nwabuisi-Heath E., Jungbauer L., Kanekiyo T., Gan M., Kim J., Eimer W.A., Estus S., Rebeck G.W., Weeber E.J., Bu G., Yu C., Ladu M.J. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. The Journal of Biological Chemistry 2012, 287:41774-41786.
23. Yue X., Lu M., Lancaster T., Cao P., Honda S., Staufenbiel M., Harada N., Zhong Z., Shen Y., Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:19198-19203.
24. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., Breitner J.C. Hormone replacement therapy and incidence of Alzheimer disease in older women: the cache county study. JAMA: The Journal of the American Medical Association 2002, 288:2123-2129.